Comparative Pharmacology
Head-to-head clinical analysis: LYRICA CR versus PHENYTEK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYRICA CR versus PHENYTEK.
LYRICA CR vs PHENYTEK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting excitatory neurotransmitter release (e.g., glutamate, norepinephrine, substance P).
Stabilizes neuronal membranes by promoting sodium efflux and inhibiting calcium influx, thereby reducing repetitive firing of action potentials. Enhances GABA-mediated inhibition and modulates voltage-gated sodium channels.
Initial 75 mg orally twice daily (150 mg/day), or 50 mg three times daily (150 mg/day). Based on efficacy and tolerability, may increase to 150 mg twice daily (300 mg/day) after 1 week, then to 225 mg twice daily (450 mg/day) if needed. Maximum dose 450 mg/day. Take with food. Administer whole; do not split, crush, or chew.
Initial dose: 100 mg orally 3 times daily; maintenance: 300-400 mg/day in 3-4 divided doses. Extended-release (ER) formulation: 300 mg orally once daily for once-daily dosing; may be increased to 400 mg once daily if needed.
None Documented
None Documented
6.3 hours (mean terminal elimination half-life); correlates with creatinine clearance, prolonged in renal impairment.
Terminal elimination half-life averages 22 hours (range 7-42 hours). Dose-dependent due to saturable metabolism; half-life increases with higher doses or in hepatic impairment.
Primarily renal excretion as unchanged drug (98-99% of absorbed dose); <0.1% biliary/fecal.
Primarily hepatic metabolism; less than 5% excreted unchanged in urine. Renal excretion of inactive metabolites accounts for ~70-80%, with biliary/fecal elimination of ~20%.
Category C
Category C
Anticonvulsant
Anticonvulsant